Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLUSF BELLUS Health		$9.77	$0.49 ▼ $2.60	$2.35B	1.55	39,610 shs	3.45 million shs
EIDX Eidos Therapeutics	$122.21	$123.21	$28.39 ▼ $132.54	$4.75B	-0.16	128,113 shs	N/A
HRTX Heron Therapeutics	$2.18 -1.8%	$2.04	$1.04 ▼ $3.73	$338.69M	1.18	2.16 million shs	865,220 shs
IRWD Ironwood Pharmaceuticals	$0.75 -3.0%	$0.69	$0.53 ▼ $7.11	$125.56M	0.3	2.55 million shs	539,756 shs
LGND Ligand Pharmaceuticals	$121.70 -2.6%	$109.40	$90.29 ▼ $129.90	$2.41B	0.84	116,807 shs	106,482 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLUSF BELLUS Health	0.00%	0.00%	0.00%	0.00%	0.00%
EIDX Eidos Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
HRTX Heron Therapeutics	-0.45%	+2.54%	+4.72%	+16.23%	-26.97%
IRWD Ironwood Pharmaceuticals	-3.53%	+4.85%	-2.90%	-17.94%	-87.99%
LGND Ligand Pharmaceuticals	+2.11%	+9.26%	+10.19%	+19.86%	+29.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLUSF BELLUS Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EIDX Eidos Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	3.7921 of 5 stars	3.5	0.0	0.0	4.2	2.7	1.7	0.6
IRWD Ironwood Pharmaceuticals	4.5086 of 5 stars	4.1	4.0	0.0	3.4	0.6	0.8	1.9
LGND Ligand Pharmaceuticals	4.0995 of 5 stars	2.5	1.0	0.0	4.4	2.1	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLUSF BELLUS Health	0.00	N/A	N/A	N/A
EIDX Eidos Therapeutics	0.00	N/A	N/A	N/A
HRTX Heron Therapeutics	3.00	Buy	$5.00	129.36% Upside
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	535.83% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	20.93% Upside

Current Analyst Ratings Breakdown

Latest LGND, IRWD, HRTX, EIDX, and BLUSF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
4/16/2025	IRWD Ironwood Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/15/2025	IRWD Ironwood Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00 ➝ $1.00
4/15/2025	IRWD Ironwood Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $0.70
4/14/2025	IRWD Ironwood Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Perform ➝ Market Perform	$3.00 ➝ $1.00
4/14/2025	IRWD Ironwood Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/11/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLUSF BELLUS Health	$30K	0.00	N/A	N/A	$0.25 per share	0.00
EIDX Eidos Therapeutics	$26.69M	177.99	N/A	N/A	$4.57 per share	26.74
HRTX Heron Therapeutics	$144.29M	2.30	N/A	N/A	($0.22) per share	-9.91
IRWD Ironwood Pharmaceuticals	$351.41M	0.35	$0.05 per share	15.69	($1.88) per share	-0.40
LGND Ligand Pharmaceuticals	$167.13M	14.05	$1.56 per share	77.78	$43.95 per share	2.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLUSF BELLUS Health	-$7.01M	-$0.10	N/A	N/A	N/A	-49,910.34%	-48.37%	-45.25%	N/A
EIDX Eidos Therapeutics	-$37.83M	-$1.03	N/A	N/A	N/A	N/A	-65.21%	-53.04%	N/A
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
IRWD Ironwood Pharmaceuticals	$880K	-$0.20	N/A	3.01	N/A	-9.89%	-1.87%	-3.93%	8/6/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	32.80	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)

Latest LGND, IRWD, HRTX, EIDX, and BLUSF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	N/A	N/A	N/A	$38.08 million	N/A
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLUSF BELLUS Health	N/A	N/A	N/A	N/A	N/A
EIDX Eidos Therapeutics	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLUSF BELLUS Health	N/A	13.87	13.87
EIDX Eidos Therapeutics	0.14	11.10	11.10
HRTX Heron Therapeutics	N/A	2.40	1.76
IRWD Ironwood Pharmaceuticals	N/A	3.34	3.34
LGND Ligand Pharmaceuticals	N/A	5.27	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLUSF BELLUS Health	N/A
EIDX Eidos Therapeutics	31.40%
HRTX Heron Therapeutics	80.01%
IRWD Ironwood Pharmaceuticals	N/A
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
BLUSF BELLUS Health	24.17%
EIDX Eidos Therapeutics	70.10%
HRTX Heron Therapeutics	5.86%
IRWD Ironwood Pharmaceuticals	12.70%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLUSF BELLUS Health	10	159.12 million	N/A	Not Optionable
EIDX Eidos Therapeutics	70	38.87 million	N/A	Not Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	141.27 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable

LGND, IRWD, HRTX, EIDX, and BLUSF Headlines

Recent News About These Companies

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)

3 hours ago | gurufocus.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock

4 hours ago | marketbeat.com

Ligand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | Benzinga

July 11 at 5:49 PM | benzinga.com

Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI

July 10 at 11:40 PM | finanznachrichten.de

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

July 10 at 8:00 AM | globenewswire.com

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What Happened

July 9 at 3:33 PM | marketbeat.com

Brokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $146.14

July 8 at 2:39 AM | americanbankingnews.com

Calamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 6, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (LGND) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from Analysts

July 5, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 4, 2025 | marketbeat.com

Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July

July 2, 2025 | finanznachrichten.de

Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals

July 2, 2025 | quiverquant.comQ

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

July 2, 2025 | globenewswire.com

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

July 2, 2025 | globenewswire.com

Lisanti Capital Growth LLC Acquires 13,565 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 29, 2025 | marketbeat.com

LGND Ligand Pharmaceuticals Incorporated - Seeking Alpha

June 26, 2025 | seekingalpha.com

Andrew Reardon Sells 500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock

June 26, 2025 | insidertrades.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,040.00 in Stock

June 25, 2025 | marketbeat.com

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

June 24, 2025 | seekingalpha.com

Advisor Resource Council Makes New $2.24 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

June 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND, IRWD, HRTX, EIDX, and BLUSF Company Descriptions

BELLUS Health OTCMKTS:BLUSF

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Eidos Therapeutics NASDAQ:EIDX

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Heron Therapeutics NASDAQ:HRTX

$2.18 -0.04 (-1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$2.18 +0.00 (+0.23%)

As of 07:37 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.75 -0.02 (-3.04%)

Closing price 04:00 PM Eastern

Extended Trading

$0.74 -0.01 (-0.97%)

As of 06:49 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ligand Pharmaceuticals NASDAQ:LGND

$121.70 -3.28 (-2.62%)

Closing price 04:00 PM Eastern

Extended Trading

$121.72 +0.02 (+0.02%)

As of 07:06 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time